Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
BCl2 antagonists, such as HA-14-1, enhanced the effects of azacitidine in these two prostate cancer models.
|
19153211 |
2009 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings identify BCL2 status in PCa as a putative predictor of (i) radiotherapy response and (ii) response to treatment with PARP inhibitor olaparib as a radiosensitizing agent.
|
29526801 |
2018 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
MiR-203 elevation suppressed prostate cancer PC-3M cell proliferation, promoted apoptosis, and weakened ADM resistance through targeted inhibiting MEK1 expression to alleviate ERK/MAPK signaling pathway and Bcl-2 expression.
|
29949147 |
2018 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Both bcl-2 and bax were expressed at higher levels in CaP than in BPH (p < 0.02).
|
16827116 |
2006 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The expression of Bcl-2 has been linked to the hormone-resistant phenotype of advanced prostate cancer.
|
11704864 |
2001 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This synergistic therapy was associated with the induction of apoptotic cell death with a decreased Bcl2 to Bax expression ratio and increased expression of cleaved caspase 3 and caspase 9 in the prostate cancer xenograft.
|
23726840 |
2013 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS Transfection of miR-143 induces the apoptosis of prostate cancer LNCap cells by down-regulating Bcl-2 expression, suggesting that Bcl-2 might be a potential therapeutic target for prostate cancer.
|
28109198 |
2017 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
BCL-xL, a hypoxia-responsive, anti-apoptotic protein of the Bcl-2 family, is also overexpressed in prostate carcinoma and many other cancers.
|
19211554 |
2009 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
|
12694817 |
2003 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We investigated the usefulness of parameters shown to be associated with prognosis in prostate cancer (p53 and bcl-2 immuno-expression, DNA cell cycle analysis and Gleason score) to stratify these incidentally identified tumors to guide clinical decision making.
|
17085199 |
2006 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC).
|
11751483 |
2001 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.
|
19117992 |
2009 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In addition, BCL-2 identified in C4-2B might contribute to the progression of androgen-refractory prostate cancer.
|
26934861 |
2016 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.
|
29316844 |
2018 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
To investigate the effect of bcl-2-mediated anti-apoptotic ability on tumor growth and progression in prostate cancer, a cell line overexpressing bcl-2 (LNCaP/bcl-2) was established by genetically engineering a prostate cancer cell line LNCaP.
|
10533903 |
1999 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that inherited BCL-2 variants may be associated with a decrease in prostate cancer susceptibility.
|
16733517 |
2006 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigate the impact of nitric oxide (NO) on RUNX2 and Bcl-2 expression in prostate cancer and further, how RUNX2 over-expression can impact tumour growth, angiogenesis and oxygenation in vivo.
|
26189652 |
2016 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of bcl-2 occurs frequently in prostate cancer and is associated with both hormonal therapy and chemotherapy resistance.
|
10190792 |
1999 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
BAG-1L (Bcl-2-associated anthanogene 1) has been found to interact with androgen receptor (AR), and has been suggested to be involved in the development of prostate cancer.
|
17503439 |
2007 |
Prostate carcinoma
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, BCL2 was also found to be frequently silenced in PCa due to aberrant promoter methylation, thus supporting a future role for apoptosis-targeted therapy in prostate cancer.
|
20464497 |
2010 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
By minimizing bcl-2 and maximizing apoptotic proteins, new systemic treatments for BC and PC can be developed that may be more effective than existing treatments.
|
17678531 |
2007 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
To determine whether oligo-induced growth factor deprivation therapy similarly enhanced expression of bcl-2 (as follows androgen deprivation) human prostate cancer derived PC-3 cells were treated in vitro with oligos directed against TGF-alpha (MR-1) and/or EGFR (MR-2).
|
9232607 |
1997 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation.
|
18475287 |
2009 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This protein can also induce PCa cell apoptosis that correlated with increasing the protein expression levels of Bax, elevating the caspase-3 activities, reducing the protein expression levels of Bcl-2 and facilitating the dephosphorylation of Akt, which is further increased by the stimulation of ephrinA5-Fc.
|
29022918 |
2017 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our group recently has also shown that bcl-2 protein expression in primary CaP is a predictor of cancer recurrence after radical prostatectomy.
|
10325496 |
1999 |